KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
Returns on capital
KalVista Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
6060.0%
avg 496.3%
ROIC
-58.9%
avg -56.0%
ROA
-49.0%
avg -41.8%
Analysis
ROE is currently the strongest return metric at 6060.0% versus its period average of 496.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Benjamin L. Palleiko | Chief Executive Officer & Director | USD 1.15M | 60 | 0 | <0.01% |
Paul K. Audhya | Chief Medical Officer | USD 773.45K | 54 | 0 | <0.01% |
Christopher Yea | Chief Development Officer | USD 708.53K | 62 | 0 | <0.01% |
Brian Piekos | Chief Financial Officer | USD 638.49K | 51 | 0 | <0.01% |
Bilal Arif | Chief Operating Officer | USD 572.46K | 54 | 0 | <0.01% |
Brian Krex | General Counsel | — | 58 | — | — |
Rachel Morten | Senior Vice President of Regulatory Affairs & QA | — | — | — | — |
Jarrod Aldom | Vice President of Corporate Communications | — | — | — | — |
Ryan Baker | Head of Investor Relations | — | — | — | — |
Christopher L. Hamblett | Senior Vice President of Corporate Development | — | — | — | — |
Linea Aspesi | Chief People Officer | — | 56 | — | — |
Compensation is shown in the reported currency; data updated Jun 13, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 11, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
41
$7.03M
Net Transaction Value
−$7.03M
Net selling
Most Active
Palleiko Benjamin L
11 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| May 27, 26May 27, 2026 | Yea Christopher Direct | Sell | $905.2K$905,224.84 |
| May 26, 26May 26, 2026 | Yea Christopher Direct | Sell | $52.6K$52,645.15 |
| May 26, 26May 26, 2026 | Audhya Paul K. Direct | Sell | $60K$59,955.49 |
| May 26, 26May 26, 2026 | Sweeny Nicole Direct | Sell | $39.9K$39,872.14 |
| May 22, 26May 22, 2026 | Palleiko Benjamin L Direct | Sell | $292.6K$292,646.35 |
| May 22, 26May 22, 2026 | Piekos Brian Direct | Sell | $39.9K$39,881.97 |
| May 22, 26May 22, 2026 | Sweeny Nicole Direct | Sell | $49.8K$49,845.77 |
| May 22, 26May 22, 2026 | Yea Christopher Direct | Sell | $63.2K$63,157.62 |
| May 22, 26May 22, 2026 | Audhya Paul K. Direct | Sell | $71.9K$71,916.11 |
| May 18, 26May 18, 2026 | Audhya Paul K. Direct | Sell | $27.6K$27,616.32 |
1–10 of 41
Summary
Insiders reported 0 buys worth $0.00 and 41 sells worth $7.03M over the last 12 months. That adds up to net selling of $7.03M. Palleiko Benjamin L was the most active insider with 11 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +68.2% (4yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +68.2% (4yr), giving you a quick read on expected growth from here.
Competitors
Who does KalVista Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about KALV's management, answered from reported figures.
Who manages KALV?
KalVista Pharmaceuticals, Inc. (KALV) lists 11 active executives. The top listed executive is Benjamin L. Palleiko, Chief Executive Officer & Director.
Are KALV insiders buying or selling?
Recent insider activity shows net selling of $30.70M.
Continue the stock analysis
Jump to another research area for this company.